Obesity drug Zepbound eases obstructive sleep apnea in trials

The results pave the way for Zepbound to potentially become the first approved treatment for the common disorder.

April 17, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | Eli Lilly's Zepbound eases obstructive sleep apnea in trials Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition. By Elaine Chen STAT+ | The next frontier in data privacy? Your brain Rising use of neurotechnology devices like Emotiv's wearable EEG and Muse headbands raises question of how to protect consumers' neural data. By Timmy Broderick STAT+ | Hospital price transparency rules are seeding a new crop of health tech startups Health care pricing data surfaced by transparency rules create an opportunity for startups to help patients fight exorbitant medical bills. By Mohana Ravindranath Adobe STAT+ | Teladoc became a household name under Jason Gorevic. Investors wanted more Gorevic's departure follows a series of missed financial projections, a precipitous decline in Teladoc's stock price, and an uninspired vision for its future. By Mario Aguilar and Mohana Ravindranath Opinion: Viral hepatitis is a silent killer. It can't be eliminated if it isn't tracked Many public health departments lack the capacity to collect data for measuring state and local burdens of viral hepatitis infections. By Heather Bradley Opinion: Kids can't wait any longer for social media safety The Kids Online Safety Act could establish common-sense safeguards to protect kids from social media pushing harmful content to minors. By Molly O'Shea

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser